CA3059290A1 - Hbv vaccine - Google Patents
Hbv vaccine Download PDFInfo
- Publication number
- CA3059290A1 CA3059290A1 CA3059290A CA3059290A CA3059290A1 CA 3059290 A1 CA3059290 A1 CA 3059290A1 CA 3059290 A CA3059290 A CA 3059290A CA 3059290 A CA3059290 A CA 3059290A CA 3059290 A1 CA3059290 A1 CA 3059290A1
- Authority
- CA
- Canada
- Prior art keywords
- hbv
- seq
- immunogen
- viral vector
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 title claims description 62
- 230000002163 immunogen Effects 0.000 claims abstract description 173
- 230000014509 gene expression Effects 0.000 claims abstract description 108
- 239000013603 viral vector Substances 0.000 claims abstract description 85
- 239000000427 antigen Substances 0.000 claims abstract description 70
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 70
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 69
- 108700024845 Hepatitis B virus P Proteins 0.000 claims abstract description 54
- 108091007433 antigens Proteins 0.000 claims abstract description 49
- 102000036639 antigens Human genes 0.000 claims abstract description 49
- 229940023147 viral vector vaccine Drugs 0.000 claims abstract description 36
- 230000035772 mutation Effects 0.000 claims abstract description 34
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 238000002255 vaccination Methods 0.000 claims abstract description 24
- 208000015181 infectious disease Diseases 0.000 claims abstract description 15
- 230000004048 modification Effects 0.000 claims abstract description 12
- 238000012986 modification Methods 0.000 claims abstract description 12
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 238000011321 prophylaxis Methods 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 44
- 150000007523 nucleic acids Chemical class 0.000 claims description 35
- 238000003776 cleavage reaction Methods 0.000 claims description 33
- 230000007017 scission Effects 0.000 claims description 33
- 239000002671 adjuvant Substances 0.000 claims description 26
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 108010028930 invariant chain Proteins 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 230000003612 virological effect Effects 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 15
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 13
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 13
- 108020001507 fusion proteins Proteins 0.000 claims description 13
- 102000037865 fusion proteins Human genes 0.000 claims description 13
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 7
- 230000004927 fusion Effects 0.000 claims description 7
- 241000701161 unidentified adenovirus Species 0.000 claims description 6
- 210000003705 ribosome Anatomy 0.000 claims description 5
- 241000990167 unclassified Simian adenoviruses Species 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 2
- 108700025184 hepatitis B virus X Proteins 0.000 claims description 2
- 208000007089 vaccinia Diseases 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 description 161
- 235000018102 proteins Nutrition 0.000 description 61
- 241000699670 Mus sp. Species 0.000 description 35
- 230000005847 immunogenicity Effects 0.000 description 29
- 150000001413 amino acids Chemical group 0.000 description 28
- 235000001014 amino acid Nutrition 0.000 description 24
- 230000004044 response Effects 0.000 description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 description 19
- 210000001744 T-lymphocyte Anatomy 0.000 description 19
- 102000018697 Membrane Proteins Human genes 0.000 description 17
- 108010052285 Membrane Proteins Proteins 0.000 description 17
- 230000005867 T cell response Effects 0.000 description 16
- 241000251730 Chondrichthyes Species 0.000 description 14
- 102100034343 Integrase Human genes 0.000 description 14
- 208000002672 hepatitis B Diseases 0.000 description 14
- 241000285424 HBV genotype C Species 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 230000028993 immune response Effects 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 9
- 108091035707 Consensus sequence Proteins 0.000 description 9
- 102000004961 Furin Human genes 0.000 description 9
- 108090001126 Furin Proteins 0.000 description 9
- 102220475376 Mitotic spindle assembly checkpoint protein MAD2B_Y63A_mutation Human genes 0.000 description 9
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 9
- 239000013256 coordination polymer Substances 0.000 description 9
- 210000004988 splenocyte Anatomy 0.000 description 9
- 241000700605 Viruses Species 0.000 description 8
- 230000007775 late Effects 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000002440 hepatic effect Effects 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 239000007927 intramuscular injection Substances 0.000 description 6
- 238000010255 intramuscular injection Methods 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 238000011725 BALB/c mouse Methods 0.000 description 5
- 101710203526 Integrase Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 230000007030 peptide scission Effects 0.000 description 4
- 238000009520 phase I clinical trial Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 206010059193 Acute hepatitis B Diseases 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 238000011510 Elispot assay Methods 0.000 description 2
- 241000214054 Equine rhinitis A virus Species 0.000 description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 2
- 241000598171 Human adenovirus sp. Species 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- IDCBOTIENDVCBQ-UHFFFAOYSA-N TEPP Chemical compound CCOP(=O)(OCC)OP(=O)(OCC)OCC IDCBOTIENDVCBQ-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 101100388071 Thermococcus sp. (strain GE8) pol gene Proteins 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 208000037628 acute hepatitis B virus infection Diseases 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000009521 phase II clinical trial Methods 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- 241000700663 Avipoxvirus Species 0.000 description 1
- 241000178270 Canarypox virus Species 0.000 description 1
- 241001217856 Chimpanzee adenovirus Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108010042634 F2A4-K-NS peptide Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000083869 Polyommatus dorylas Species 0.000 description 1
- 241001672814 Porcine teschovirus 1 Species 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 101800000684 Ribonuclease H Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 241001417495 Serranidae Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000404975 Synchiropus splendidus Species 0.000 description 1
- 241001648840 Thosea asigna virus Species 0.000 description 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 208000016350 chronic hepatitis B virus infection Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000011194 good manufacturing practice Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- CSHFHJNMIMPJST-HOTGVXAUSA-N methyl (2s)-2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoate Chemical compound NCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)OC)CC1=CC=CC=C1 CSHFHJNMIMPJST-HOTGVXAUSA-N 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000001403 relative X-ray reflectometry Methods 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- YXZRCLVVNRLPTP-UHFFFAOYSA-J turquoise blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Cu+2].NC1=NC(Cl)=NC(NC=2C=C(NS(=O)(=O)C3=CC=4C(=C5NC=4NC=4[N-]C(=C6C=CC(=CC6=4)S([O-])(=O)=O)NC=4NC(=C6C=C(C=CC6=4)S([O-])(=O)=O)NC=4[N-]C(=C6C=CC(=CC6=4)S([O-])(=O)=O)N5)C=C3)C(=CC=2)S([O-])(=O)=O)=N1 YXZRCLVVNRLPTP-UHFFFAOYSA-J 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/26—Endoribonucleases producing 5'-phosphomonoesters (3.1.26)
- C12Y301/26004—Ribonuclease H (3.1.26.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1705765.4 | 2017-04-10 | ||
| GBGB1705765.4A GB201705765D0 (en) | 2017-04-10 | 2017-04-10 | HBV vaccine |
| PCT/GB2018/050948 WO2018189522A1 (en) | 2017-04-10 | 2018-04-10 | Hbv vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3059290A1 true CA3059290A1 (en) | 2018-10-18 |
Family
ID=58744773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3059290A Pending CA3059290A1 (en) | 2017-04-10 | 2018-04-10 | Hbv vaccine |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20200113998A1 (enExample) |
| EP (1) | EP3609535B1 (enExample) |
| JP (1) | JP7326157B2 (enExample) |
| KR (1) | KR102700586B1 (enExample) |
| CN (2) | CN110913899B (enExample) |
| AU (1) | AU2018251241B2 (enExample) |
| CA (1) | CA3059290A1 (enExample) |
| DK (1) | DK3609535T3 (enExample) |
| ES (1) | ES3036962T3 (enExample) |
| GB (1) | GB201705765D0 (enExample) |
| MX (1) | MX2019012101A (enExample) |
| MY (1) | MY202396A (enExample) |
| PH (1) | PH12019502310A1 (enExample) |
| SG (1) | SG11201909353VA (enExample) |
| WO (1) | WO2018189522A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
| US20220339281A1 (en) * | 2019-03-05 | 2022-10-27 | GalxoSmithKline Biologicals SA | Hepatitis b immunisation regimen and compositions |
| US20220305107A1 (en) * | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi |
| WO2020255055A1 (en) * | 2019-06-20 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof |
| CA3149415A1 (en) | 2019-08-29 | 2021-03-11 | Eric Bruening | Hepatitis b virus vaccines |
| EP4458975A3 (en) * | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| WO2021243149A2 (en) * | 2020-05-28 | 2021-12-02 | President And Fellows Of Harvard College | Protein covariance networks reveal interactions important to the emergence of sars coronaviruses as human pathogens |
| PH12023550030A1 (en) * | 2020-07-08 | 2024-03-11 | Janssen Sciences Ireland Unlimited Co | Rna replicon vaccines against hbv |
| JPWO2022071513A1 (enExample) | 2020-10-02 | 2022-04-07 | ||
| TW202245809A (zh) * | 2020-12-18 | 2022-12-01 | 美商詹森藥物公司 | 用於治療b型肝炎病毒感染之組合療法 |
| CN115595312A (zh) * | 2021-06-28 | 2023-01-13 | 中国农业大学（Cn） | 一种重组腺病毒及其应用 |
| US20250000968A1 (en) * | 2021-11-12 | 2025-01-02 | The United States of America, as represented by the Secretary,Department of Health and Human Service | Sars-cov-2 spike fused to a hepatitis b surface antigen |
| US20230310591A1 (en) | 2021-12-07 | 2023-10-05 | Vaccitech (Uk) Limited | Vaccine Boost Methods and Compositions |
| WO2024193905A1 (en) * | 2023-03-17 | 2024-09-26 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Hbv antigen formulation for treating hepatitis b |
| GB202317925D0 (en) | 2023-11-23 | 2024-01-10 | Spybiotech Ltd | Vaccines |
| CN118593695B (zh) * | 2024-08-07 | 2024-10-22 | 山东兴瑞生物科技有限公司 | 一种用于治疗HBV感染的siRNA和mRNA联合疫苗 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7709224B2 (en) * | 2003-06-03 | 2010-05-04 | Biosante Pharmaceuticals, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
| CN101573449B (zh) * | 2006-08-14 | 2013-09-18 | 浦项工大产学协力团 | 用于治疗慢性乙型肝炎的dna疫苗及其制备方法 |
| NZ598000A (en) * | 2009-08-07 | 2013-10-25 | Transgene Sa | Composition for treating hbv infection |
| AP2013007110A0 (en) * | 2011-02-12 | 2013-09-30 | Globeimmune Inc | Yeast-based therapeutic for chronic hepatitis B infection |
| TWI623618B (zh) * | 2011-07-12 | 2018-05-11 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
| CN103173492B (zh) * | 2013-03-12 | 2014-08-13 | 中国人民解放军白求恩国际和平医院 | 携带外源基因的复制型hbv载体、其转染后产生的重组hbv，和相应的制备方法与应用 |
| GB201321384D0 (en) * | 2013-12-04 | 2014-01-15 | Isis Innovation | Molecular adjuvant |
-
2017
- 2017-04-10 GB GBGB1705765.4A patent/GB201705765D0/en not_active Ceased
-
2018
- 2018-04-10 KR KR1020197031896A patent/KR102700586B1/ko active Active
- 2018-04-10 CN CN201880028408.6A patent/CN110913899B/zh active Active
- 2018-04-10 WO PCT/GB2018/050948 patent/WO2018189522A1/en not_active Ceased
- 2018-04-10 AU AU2018251241A patent/AU2018251241B2/en active Active
- 2018-04-10 JP JP2019555196A patent/JP7326157B2/ja active Active
- 2018-04-10 MY MYPI2019005911A patent/MY202396A/en unknown
- 2018-04-10 MX MX2019012101A patent/MX2019012101A/es unknown
- 2018-04-10 CA CA3059290A patent/CA3059290A1/en active Pending
- 2018-04-10 US US16/604,221 patent/US20200113998A1/en not_active Abandoned
- 2018-04-10 ES ES18719248T patent/ES3036962T3/es active Active
- 2018-04-10 EP EP18719248.9A patent/EP3609535B1/en active Active
- 2018-04-10 SG SG11201909353V patent/SG11201909353VA/en unknown
- 2018-04-10 DK DK18719248.9T patent/DK3609535T3/da active
- 2018-04-10 CN CN202410387306.0A patent/CN118576699A/zh active Pending
-
2019
- 2019-10-08 PH PH12019502310A patent/PH12019502310A1/en unknown
-
2023
- 2023-06-06 US US18/206,249 patent/US20240115694A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240115694A1 (en) | 2024-04-11 |
| JP7326157B2 (ja) | 2023-08-15 |
| SG11201909353VA (en) | 2019-11-28 |
| KR20200024130A (ko) | 2020-03-06 |
| MY202396A (en) | 2024-04-25 |
| GB201705765D0 (en) | 2017-05-24 |
| KR102700586B1 (ko) | 2024-08-30 |
| JP2020516264A (ja) | 2020-06-11 |
| AU2018251241B2 (en) | 2025-04-17 |
| EP3609535A1 (en) | 2020-02-19 |
| CN118576699A (zh) | 2024-09-03 |
| DK3609535T3 (da) | 2025-08-18 |
| US20200113998A1 (en) | 2020-04-16 |
| ES3036962T3 (en) | 2025-09-25 |
| CN110913899B (zh) | 2024-04-19 |
| WO2018189522A1 (en) | 2018-10-18 |
| MX2019012101A (es) | 2019-12-11 |
| AU2018251241A1 (en) | 2019-10-31 |
| EP3609535B1 (en) | 2025-06-25 |
| PH12019502310A1 (en) | 2020-09-21 |
| CN110913899A (zh) | 2020-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240115694A1 (en) | Hbv vaccine | |
| KR102873711B1 (ko) | Hbv를 치료하기 위한 수단 및 방법 | |
| ES2376010T3 (es) | Prote�?na de fusión de transcriptasa inversa de la telomerasa, nucleótidos que la codifican y usos de la misma. | |
| DK2968493T3 (en) | Enhanced poxvirus vaccines. | |
| JP7317017B2 (ja) | Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよびその使用 | |
| US8853379B2 (en) | Chimeric poly peptides and the therapeutic use thereof against a flaviviridae infection | |
| CN107847575B (zh) | 用于猪生殖与呼吸综合症及猪圆环病毒相关疾病的疫苗组合物 | |
| CN101573449A (zh) | 用于治疗慢性乙型肝炎的dna疫苗及其制备方法 | |
| IL274409B2 (en) | T-cell vaccine booster | |
| JP2021506300A (ja) | Ｂ型肝炎ウイルス（ｈｂｖ）に対する免疫応答を誘導するための方法および組成物 | |
| IL298834A (en) | A recombinant modified vaccinia virus ankara (mva) vaccine against coronavirus disease | |
| JP2007523610A (ja) | 癌胎児抗原をコードする合成遺伝子およびその使用 | |
| Zhang et al. | Immunogenicity of plasmid DNA encoding the 62 kDa fragment of Schistosoma japonicum myosin | |
| US9676825B2 (en) | Chimeric vaccine antigens against hepatitis C virus | |
| ES2282156T3 (es) | Vacuna de acido nucleico. | |
| JP2002528519A (ja) | 抗腫瘍効果を有する、抗原性タンパク質をコードしているｄｎａを含む医薬組成物 | |
| KR100841732B1 (ko) | 만성 ｂ형 간염의 치료를 위한 ｄｎａ 백신 및 그의 제조방법 | |
| US11154613B2 (en) | HCV vaccines | |
| KR20240053097A (ko) | 사스 코로나바이러스 2 베타 변이주 항원 및 이를 포함하는 고효능 백신 조성물 | |
| WO2023187366A1 (en) | Immunogenic compositions for the prevention of influenza a | |
| Babikyan | Comparative analysis of anti-amyloid β immune responses generated after different toutes of immunization with plasmid enconding Aβ-peptide immunogen fused with IL4 | |
| ZA200508013B (en) | Synthetic gene encoding human carcinoembryonic antigen and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230406 |
|
| EEER | Examination request |
Effective date: 20230406 |
|
| EEER | Examination request |
Effective date: 20230406 |